ClinicalTrials.gg
CompletedNCT06854783Updated Feb 4, 2026

Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

A Phase 1 interventional study of Cannabidiol in Pharmacokinetics, sponsored by Tiamat Australia Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Tiamat Australia Pty Ltd · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetics, safety, tolerability and food effect of investigational drug MRX1 in healthy adults.

Read the detailed description

MRX1 is an oral solution containing cannabidiol.

The primary objective of this study is the assess the pharmacokinetic profile of MRX1 at two doses when administered twice daily in healthy adults. The secondary objectives are to assess the safety and tolerability of MRX1 and to characterise the effect of a high fat, high calorie meal on the pharmacokinetics of a single dose of MRX1.

A total of 20 healthy volunteers (10 male and 10 female) will be sequentially enrolled into 2 treatment groups, with 5 males and 5 females in each group.

The duration of the study is up to 52 days per participant for Group A and 37 days per participant for Group B, including screening and follow up.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

This is the only study on the registry with Tiamat Australia Pty Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide voluntary, written
  • Males and females, aged 18 to 55 years inclusive at time of informed consent.
  • Total body weight ≥50 kg and (BMI) between 18 and 32 kg/m2 inclusive.
  • Women of (WOCBP) must have a negative pregnancy test at Screening and Day -1.
  • WOCBP must agree to the use a highly effective (refer to Appendix 11.1) from Screening through 30 days following the last dose of study drug.
  • Male participants must agree to use highly effective birth control including condom (refer to Appendix 11.1) from Screening through 90 days following the last dose of study drug. Male participants with female partners that are surgically sterile or post menopausal (defined as being amenorrhoeic for at least 12 months without an alternative medical cause), or male participants who have undergone sterilisation and have had testing to confirm the success of the sterilisation, may also be included and will not be required to use above-described methods of contraception. Male participants must also agree not to donate sperm up to 90 days following the last dose of study drug.
  • Considered healthy, as determined by medical evaluation by the Investigator including medical history and physical examination.
  • Vital signs after 5 minutes resting in supine position within the following ranges: Systolic blood pressure: 90 to 140 mmHg inclusive; Diastolic blood pressure: 40 to 90 mmHg inclusive; Heart rate: 40 to 100 bpm inclusive.
  • Standard 12-lead with parameters (average of triplicate readings) after 10 minutes in supine position within the following ranges: QRS \<120 msec; \<500 msec; QTc ≤450 msec (both genders); PR interval ≥120 to ≤220 msec.
  • Negative tests for , HBcAb (if HBsAg positive), anti-, and antibody at Screening (positive anti-HCV antibody allowed if HCV PCR is negative).
  • Screening and Day -1 safety laboratory test values within normal ranges. Out of normal range values may be accepted by the Investigator if not considered , with the exception of the following: or AST >1.5 x (ULN); Total, indirect, or direct >1.5 x ULN. Participants with Gilbert's syndrome with indirect bilirubin outside of the normal range will be excluded from the study.
  • Willing to refrain from consumption of alcohol as follows: Group A: for at least 48 hours prior to Screening, Day -1, and Day 20, and throughout the in-patient confinement periods and post-dose follow-up visits (consumption of alcohol is permitted during the outpatient ); Group B: for at least 48 hours prior to Screening and Day -1, and throughout the study.
  • Willing to defer blood donations to a blood service for minimum of 30 days following the last dose of study drug.
  • In the opinion of the Investigator, is willing and able to comply with and understand study requirements and be available for the required study visits.

Exclusion criteria

Exclusion Criteria:

  • Female participant who is pregnant or breastfeeding, or planning to become pregnant or breastfeed, or planning to donate ova during study participation.
  • History or presence of a medical condition that, in the opinion of the Investigator, would interfere with the evaluation of the study drug or lead to increased risk of harm.
  • Presence of any chronic medical condition requiring ongoing treatment.
  • Any illness, medical/surgical procedure, or trauma within 4 weeks prior to Screening, as per Investigator judgement.
  • Documented evidence of current or past cardiovascular disease including cardiac arrhythmias or family history of congenital long syndrome, Brugada syndrome, or unexplained sudden cardiac death.
  • Any gastrointestinal surgery or condition or disease that could affect drug absorption, distribution, or excretion (e.g., gastrectomy, cholecystectomy, diarrhea, recurrent nausea/vomiting).
  • History of of any organ system (other than localised basal cell carcinoma of the skin or in situ cervical cancer considered treated and cured), treated or untreated, within 5 years before Screening, regardless of if there is no evidence of local recurrence or .
  • History of schizophrenia, bipolar disorder psychoses, disorders requiring lithium, attempted or planned suicide, or any other severe (disabling) chronic psychiatric diagnosis including generalised anxiety and obsessive-compulsive disorders. Hospitalisation within 5 years before Screening due to psychiatric illness or due to danger to self or others.
  • Current use (or within the 3 months prior to Screening) of other cannabinoid or cannabis products.
  • History of allergy or other adverse reaction to cannabinoid or cannabis products at any time in the past or known or suspected to any of the components of the formulation.
  • Current or recent (within 2 months prior to Screening) use of any tobacco or nicotine products (including e-cigarettes, vaping, or dipping) at >5 cigarettes per week or equivalent. Causal/social smokers (≤5 cigarettes per week or equivalent) are permitted.
  • History of substance abuse disorder(s), as determined by the Investigator, within 5 years of Screening, including but not limited to alcohol, illicit drugs, and inappropriate use of prescription drugs.
  • Positive urine drug test or alcohol breath test at Screening or Day 1, unless there is an explanation deemed acceptable by the Investigator and/or the participant tests negative upon re-test (one re-test permitted per scheduled time point).
  • Use of any prescription medicines or marijuana within 14 days of Day -1 or use of any nonprescription medicines, supplements, or vaccines within 7 days of Day 1. Occasional (PRN) paracetamol (up to 2 g/day) or ibuprofen (up to 1.2 g/day) use may be permitted, at Investigator discretion. Hormonal are permitted.
  • Consumption of food and/or beverages containing Seville oranges or Seville orange juice, or grapefruit or grapefruit juice, or poppy seeds within 7 days prior to Day -1.
  • Consumption of caffeine/xanthine products within 24 hours prior to Day -1.
  • Use of any drug within 30 days or \<5 half-lives, whichever is longer, prior to first dose of study drug.
  • Donation or receipt of any blood or blood products at a blood bank or donation centre within 30 days prior to Screening.
  • Identified as a site employee of the Investigator or study centre, with direct involvement in the proposed study or other studies under the direction of that Investigator or study centre, as well as family members (i.e., immediate, husband, wife or de facto and their children, adopted or natural) of the site employees or the Investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Group A Low Dose

    Group A: Period 1 (Fasted): Cannabidiol at 2.5 mg/kg of body weight, administered twice daily (BID) for 5 days, with a single dose administered on the morning of Day 6 (n=10). All doses will be administered in a fasted state. Following a 14-day washout period, all participants will enter Period 2. Period 2 (Fed): Cannabidiol at 2.5 mg/kg of body weight, administered once on the morning of Day 21 following consumption of a standardised high fat, high calorie meal (n=10).

    Drug: Cannabidiol

  • Experimental
    Group B High Dose

    Group B Period 1 (Fasted): Cannabidiol at 7.5 mg/kg of body weight, administered BID for 5 days, with a single dose administered on the morning of Day 6 (n=10). All doses will be administered in a fasted state.

    Drug: Cannabidiol

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration [Cmax]

    Maximum observed concentration for CBD, 7-OH-CBD and 7-COOH-CBD.

    Time frame: Days 1, 6 and 21

  2. Pre-dose concentration [Ctrough]

    Pre-dose concentration inclusive of CBD, 7-OH-CBD and 7-COOH-CBD.

    Time frame: From Day 2 to Day 6.

  3. Time to maximum observed concentration [Tmax]

    Time to maximum observed concentration of CBD, 7-OH-CBD and 7-COOH-CBD.

    Time frame: Days 1 and 6.

  4. Area under the plasma concentration time curve 0-12 hours [AUC0-12]

    The area under the plasma concentration-time curve, from time 0 (time of dosing) to 12 hours for CBD, 7-OH-CBD and 7-COOH-CBD.

    Time frame: Days 1, 6 and 21

  5. Area under the plasma concentration-time curve 0-24 [AUC0-24]

    The area under the plasma concentration-time curve, from time 0 (time of dosing) to 24 hours for Group B and Group A, Period 1 for CBD, 7-OH-CBD and 7-COOH-CBD.

    Time frame: Day 1

Secondary outcomes

  1. Frequency and severity of adverse events

    The frequency and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI) as assessed by CTCAE v5.0.

    Time frame: From Day 1 to end of study at Day 24.

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Oct 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Mar 3, 2025
StartActual
Jul 14, 2025
Primary completionActual
Oct 1, 2025
CompletionActual
Oct 1, 2025
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06854783
Lead sponsor
Tiamat Australia Pty Ltd
Collaborators
Ananda Pharma plc
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Jul 14, 2025
Primary completion
Oct 1, 2025
Completion
Oct 1, 2025
Last update
Feb 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion